Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
20 déc. 2021 08h00 HE | FibroGen, Inc.
Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones...